About Us

iX Biopharma Ltd is a pharmaceutical and nutraceutical company listed on the Singapore Exchange Securities Trading Limited (SGX-ST). The company, together with its subsidiaries (the Group) operate a fully integrated business model which includes drug formulation, clinical studies, regulatory affairs, manufacturing and sales, which provides the Group with the significant operational benefits from lower cost of sales, enhanced operating efficiencies, better quality control, shorter time-to-market and intellectual property protection. The Group focuses on the development and commercialization of therapies for conditions with unmet medical needs using its cutting edge, patented sublingual delivery technology, WaferiX. Through its wholly owned subsidiary iX Syrinx, it operates a full-service manufacturing facility and chemical testing laboratory in Australia. Entity, the Group's next-generation nutraceuticals, are a powerful combination of groundbreaking science and the very best extracts nature has to offer. Manufactured under stringent conditions, these pioneering health products work to increase your quality of life by delaying the development of chronic illnesses and disabilities.